Incyte

Incyte Gross Profit/Assets

The Gross Profit to Assets Ratio of Incyte (INCY) as of Nov 16, 2026 is 68.54 %. In the previous year, Gross Profit to Assets Ratio was 72.17 % — a change of -5.03% (lower).

Gross Profit/Assets

68.54 %

YoY

-5.03%

Last updated:

Gross Profit to Assets Ratio of Incyte is 2025 68.54 % . Gross Profit to Assets Ratio of Incyte was 2024 72.17 % . It decreases by -5.03% lower compared to the previous year.

The Incyte Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2018
67.57 USD
Jan 1, 2019
59.66 USD
Jan 1, 2020
71.20 USD
Jan 1, 2021
57.47 USD
Jan 1, 2022
54.57 USD
Jan 1, 2023
50.73 USD
Jan 1, 2024
72.17 USD
Jan 1, 2025
68.54 USD
The Incyte Gross Profit/Assets history
YEARGross Profit/AssetsYoY
68.54 %-5.03%
72.17 %+42.26%
50.73 %-7.04%
54.57 %-5.04%
57.47 %-19.28%
71.20 %+19.34%
59.66 %-11.70%
67.57 %+6.81%
63.27 %-1.04%
63.93 %-11.38%
72.14 %+17.76%
61.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Incyte Stock analysis

What does Incyte do? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incyte stock

Gross Profit to Assets Ratio of Incyte is 68.54 % in 2025.

Gross Profit to Assets Ratio of Incyte changed from 72.17 % to 68.54 %, representing a -5.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Incyte since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Incyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Incyte

All Key Metrics — Incyte